Kornimate/medical-research-clean huggingface dataset:
bobath approach for trunk control in acute stroke patients

Conditions: Stroke, Acute

Summary: in stroke patients, the impairment of the trunk affects many functions negatively. for this reason training of the trunk is necessary in the early period. taking into account of literature, various approaches have been used to improve sitting balance and trunk control such as conventional physiotherapy for stroke patients . bobath concept is another method used for stroke rehabilitation. when the studies about stroke rehabilitation are investigated, it is seen that most of the studies included only chronic patients and bobath concept did not adequately take place in literature about trunk training. the aim of this study is to determinate effectiveness of the bobath based trunk training on trunk control in acute stroke patients.

in stroke patients, the impairment of the trunk affects many functions negatively. for this reason training of the trunk is necessary in the early period. taking into account of literature, various approaches have been used to improve sitting balance and trunk control such as conventional physiotherapy for stroke patients . bobath concept is another method used for stroke rehabilitation. trunk control is an important issue in the bobath approach since the acute period. it seems that the bobath method, which includes both approaches to increase postural control and sitting, as well as applications to increase the sensation, seems to be an appropriate method to improve body control in stroke patients. when the studies about stroke rehabilitation are investigated, it is seen that most of the studies included only chronic patients and bobath concept did not adequately take place in literature about trunk training in acute stroke. the aim of this study is to determinate effectiveness of the bobath based trunk training on trunk control in acute stroke patients.

Eligibility criteria:
inclusion criteria: * patients scoring ≥14 on glasgow coma scale and mini mental test\>24 exclusion criteria: * patients scoring \<14 on glasgow coma scale * patients with recurrent strokes * patients with orthopedic or neurological disorders (other than strokes) that might affect their motor performance

Keywords: physiotherapy trunk control bobath concept stroke rehabilitation
use of a nerve regeneration conduit (nervfix®) in the treatment of nerve section of the wrist

Conditions: Nerve Injury; Nerve Lesion

Summary: the purpose of this open, multicenter trial is to assess the impact of a nerve regeneration conduit made of allogeneic artery or vein from umbilical cord lining on the regeneration of wrist nerve.


Eligibility criteria:
inclusion criteria: * men and women over 18 years of age and under 65 years of age * one wrist nerve section ( medial, ulnar) with a minimum of 2 mm and maximum gap of 2 cm evaluated during the surgical procedure (sunderland grade v) * inclusion of direct suture with wrapping or nerve defect with nervfix for nerve junction * poor outcome on the mackinnon-dellon scale: \< s3 * within 1 month of the injury or accident event and/or at the time of the injury (emergency procedure) * any damaged artery must be repaired * patient with no poor vascularization risk (no surgical treatment of vessel section) or no disease linked to poor vascularization. * patient who received the study information and provided consent * patients who are members or the beneficiary of a national health insurance plan exclusion criteria: * breast feeding women or women without effective contraception (if no effective contraception: a pregnancy test is mandatory) * digital nerve section * pregnant or breast feeding women: women of childbearing age will be asked to undergo a pregnancy test before being enrolled into the study and to use an effective birth control method * patient who suffered amputation of the hand in question * surgical site infection or necrotic area; tendon and/or bone damage * underlying motor or sensory disorder that could compromise the evaluation; inflammatory arthritis causing pain * disease that compromises healing such as diabetes, alcoholism or skin disorder * vascular disease leading to reduced blood flow or altered microvascularisation such as raynaud's disease * subjects who are unlikely to follow through with rehabilitation or who could be addicted to drugs or alcohol; heavy smokers will be asked to stop smoking voluntarily * persons confined by a judicial or administrative decision * adults subject to legal protection measures or who are unable to provide their consent
genetic modifiers for 22q11.2 syndrome

Conditions: 22q11.2 Deletion Syndrome

Summary: the purpose of the project is the determination of how the deletion of dna from chromosome 22 at the q11.2 band causes the phenotypes observed in velo-cardio-facial syndrome (vcfs). in other words, the purpose remains genotype-to-phenotype matching. current methods includes the use of whole genome chips and microarray analysis. blood samples are collected for dna from every patient who consents from the vcfs center at upstate medical university. they are examined for phenotypic features consistent with our typical clinical evaluation. the information from these examinations will be entered anonymously into a database. genomic information is then matched to clinical phenotype with appropriate statistical method applied.


Eligibility criteria:
inclusion criteria: * fish confirmed diagnosis of 22q11.2 deletion syndrome exclusion criteria: * none

Keywords: 22q11.2 deletion syndrome velo-cardio-facial syndrome congenital anomalies mental illness congenital heart disease
progesterone vs clobetasol propionate in vulvar lichen sclerosus

Conditions: Vulvar Lichen Sclerosus

Summary: this is a randomized trial comparing progesterone with conventional clobetasol propionate in patients with vulvar lichen sclerosus.

background a total of 62 female patients with first diagnosis of lichen sclerosus will be treated daily with either topical progesterone 8% or clobetasol propionate 0.05% for 12 weeks. response to the treatment will be evaluated by macroscopic description of the dermatologic phenotype by using a specific lichen sclerosus score and photography-documentation. the symptoms and quality of life of the patients will be evaluated by standardized questionnaires. additionally, tissue samples will be taken before and again after 12 weeks of treatment to evaluate the response status. objective the purpose of this study is to compare progesterone with conventional clobetasol propionate in a superiority trial. methods prospective, randomized, controlled, superiority phase ii pilot trial. patients will be randomized 1:1 to either progesterone or clobetasol propionate, with patients, physicians, assessors and analysts being blinded.

Eligibility criteria:
inclusion criteria: * signed informed consent * consent to biopsy at start and end of therapy * suspicion of lichen sclerosus * pre-menopausal * age ≥18 years exclusion criteria * prior surgery at the vulva, with exception of episiotomy * pregnancy * signs of infection with human papilloma virus at the vulva * vulvar intraepithelial neoplasia (vin) * known generalised autoimmune disease * lichen sclerosus since childhood * prior therapy with topic clobetasol propionate or other immunosuppressives (tacrolimus or pimecrolimus) at the vulva * atopic diathesis and/or contact allergy * systemic immunosuppressive therapy * genital infection within the last four weeks (eg., condyloma acuminata, candidiasis)

Keywords: vulvar lichen sclerosus progesterone clobetasol randomized controlled trial
predicting the efficacy in advanced gastric cancer.

Conditions: Gastric Cancer; Chemotherapy Effect; Paclitaxel; Ramucirumab

Summary: with advances in chemotherapy for gastric cancer, it is important to identify patients who will respond effectively to specific therapies. this longitudinal study aimed to establish a liquid-biopsy assay that can predict response to ramucirumab plus paclitaxel therapy in patients with advanced gastric cancer.

the combination of paclitaxel and ramucirumab is a potent standard second-line therapy for patients with advanced gastric cancer, but approximately 30% of patients do not respond to treatment. failure to respond to second-line therapy can lead not only to disease progression, but also to deterioration of the patient's health and loss of the opportunity to receive other treatments that originally had the potential to be curative. this study aims to predict the efficacy of second-line treatment (paclitaxel plus ramucirumab) in patients with gastric cancer using liquid biopsies (small rna). prediction using pre-treatment blood may allow patients who do not respond to treatment to choose other treatment options. this study aims to establish a tool that will enable noninvasive pre-treatment selection, which could lead to personalized treatment.

Eligibility criteria:
inclusion criteria: 1. unresectable or recurrent gc histologically confirmed to be primary adenocarcinoma of the stomach. 2. age over 20 years. 3. eastern cooperative oncology group performance status score of 0-2. 4. written informed consent following full study information is provided to the patient. 5. progression or intolerance for first-line chemotherapy comprising fluorinated pyrimidine and platinum anticancer drugs (cisplatin or oxaliplatin) for advanced gc. 6. presence of evaluable lesions as confirmed using a computed tomography (ct) or magnetic resonance imaging. exclusion criteria: 1. patients with a life expectancy of shorter than 3 months 2. patients with severe complications (angina pectoris, myocardial infarction, or arrhythmia) or uncontrollable diabetes mellitus, blood hypertension, or bleeding tendency. 3. patients with a history of serious allergic reactions or serious drug allergy. 4. patients with a clinically relevant mental disorder that prohibits response to questionnaires. 5. patients for whom the attending physician considered that enrollment in the study is inappropriate.
study of the telomere-telomerase system and the expression of candidate genes in the leukocytes of patients with depressive disorder: search for peripheral markers of somatic stress

Conditions: Depressive Disorder

Summary: the mechanisms of oxidative stress and inflammation involved in mood disorders are factors of chronicity and severity. these mechanisms induce a phenomenon of accelerated cellular senescence and are reflected by alterations in systemic gene expression detectable in leukocytes in peripheral blood. the genetic markers of these mechanisms are clinically significant markers. the identification of new genetic markers will make it possible to improve evaluations of the severity and somatic consequences of depressive syndromes.


Eligibility criteria:
inclusion criteria: * persons who have given their written informed consent * absence of a diagnosis of major depressive disorder throughout the study and no history of psychiatric disorders * diagnosis of a first episode of a major depressive disorder * diagnosis of a recurrent major depressive disorder (at least three episodes) with or without resistance to therapy remarks: * the diagnosis of major depressive disorder with characteristics of melancholy must be clearly mentioned in the case report form but is not a reason for not being included in the study * the presence of a recent or older attempted suicide must lead to a careful clinical assessment of the diagnosis of depressive disorder and must be clearly mentioned in the case report form. exclusion criteria: * persons not covered by the national health insurance agency * psychotic or bipolar disorders * severe personality disorders * cardiovascular disease, proven inflammatory disease and cancer * persons unable to give their consent personally, * persons in emergency situations, * pregnant women, * breast-feeding women
evaluation of the mobility of the digital flexor tendons

Conditions: Flexor Digitorum Longus on the Right; Flexor Digitorum Longus on the Left; Tendon Rupture; Tendon Injury - Hand

Summary: to study flexor tendon excursion in the hand after surgery by dynamic mri

the study of the movement of the digital flexor tendon operated on mri could lead to a better understanding of the biomechanics of this tendon after surgery, to objectively assess the repair of the tendon and the recovery of its mobility. the visualization of the aspect and the movement of this operated tendon would make it possible to adapt the rehabilitation for each patient and to prevent the occurrence of complications which limit functional recovery and source of handicap. the analysis of the imaging in patients evolving would establish useful criteria the surgeon to judge the evolution of the operated tendon. the first step consists in evaluating the feasibility of the acquisition of dynamic sequences in mri and the possibility of observing the movement of the flexor tendon operated during the mobilization of the finger, and comparing the biomechanical data obtained with those of the nonoperated tendons and experimental models.

Eligibility criteria:
inclusion criteria: * flexor tendon injury in zone 2 * treatment by surgery * insufficient functional outcome after surgery * mri requested by surgeon exclusion criteria: * pregnancy * mri contraindications * previous surgery on the hand * rheumatic disorder
bronchoscopic microwave intervention treatment in advanced central nsclc

Conditions: Effect Increased; Safety Issues

Summary: a randomized, prospective study of the efficacy and safety of the first-line treatment in advanced central non-small cell lung cancer patients by anti-pd-1 / pd-l1 monoclonal antibody and chemotherapy versus anti-pd-1 / pd-l1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention

this study is a randomized, prospective study, which will analyze the efficacy and safety of the first-line treatment in advanced central non-small cell lung cancer patients by anti-pd-1 / pd-l1 monoclonal antibody and chemotherapy versus anti-pd-1 / pd-l1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention. the efficacy will include objective response rate, disease control rate, progression-free survival, and overall survival. the safety will include adverse events and quality of life.

Eligibility criteria:
inclusion criteria: * advanced central non-small cell lung cancer patients, untreated, tolerating bronchoscopy exclusion criteria: * contraindications to tracheoscopy, chemotherapy, and immunotherapy

Keywords: anti-pd-1 / pd-l1 monoclonal antibody chemotherapy bronchoscopic microwave intervention advanced central non-small cell lung cancer patients
in-vivo wettability grading and assessment study

Conditions: Myopia

Summary: the purpose of this study is to investigate the front surface wettability of soft contact lenses while on eye.


Eligibility criteria:
inclusion criteria: * is at least 17 years of age * has read and signed an information consent letter * is a current daily wear contact lens wearer * has acceptable fit with the study lenses * has had an ocular exam in the last two years * other protocol-defined inclusion criteria may apply exclusion criteria: * has any ocular disease * has undergone corneal refractive surgery or is aphakic * has any systemic disease affecting ocular health * is pregnant or lactating * other protocol-defined exclusion criteria may apply
secure self-monitoring through a combination of connected objects: implementation in covid-19 patients monitored at home

Conditions: Covid19

Summary: currently, covid+ infected patients who are on ambulatory home monitoring self-assess their health status simply by completing questionnaires and measuring their temperature twice a day. the securadom project proposes to facilitate the follow-up of covid+ or suspected covid+ infected patients, followed at home, by collecting clinical signs on a telephone application and to monitor physiological safety parameters (respiratory rate, heart rate, temperature, blood pressure, activity) using connected objects developed by the company withings. this daily monitoring, which can be transmitted by patients to the doctors in charge of their surveillance, will improve the quality and safety of home monitoring.


Eligibility criteria:
inclusion criteria: * adults, men and women, 18 y/o or more * patient diagnosed covid positive with rt-pcr positive or very suggestive symptoms and a contagion (contact with sick subjects) that can be managed on an outpatient basis. * patient in possession of a smartphone (with android or ios) allowing the installation of the withings health mate application * patient with access to an internet connection for the use of withings connected products at the containment site * voluntary patient who has not objected to his or her participation * patient affiliated to or beneficiary of a social security scheme exclusion criteria: * pregnant women * patient with severe symptoms requiring hospitalization as recommended by the french ministry of health (23/03/2020) * patient without social protection or affiliated to the ame (state medical aid) * person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure (patient under guardianship or curatorship) articles l1121-5 to l1121-8 * patient who, in the judgment of the investigator, may not be cooperative or respectful of the obligations inherent to participation in the study.
magic study: more access to group integrative care

Conditions: Chronic Pain

Summary: chronic pain impacts about 20% of us adults. though non-pharmacologic, integrative pain management therapies are now considered first-line treatment by clinical guidelines, these therapies are still rarely covered by health insurance and therefore inaccessible to lower-income individuals. the integrative medical group visit (imgv) program was developed to offer low-income, diverse patients with chronic pain an introduction to integrative pain management approaches, through a model that is covered by health insurance under existing billing codes. an initial pragmatic randomized control trial found that imgv led to significant improvement in mental health related quality of life and lower use of high-cost care. however, there has been little research investigating the implementation of imgv, and none in federally-qualified health centers (fqhcs), where the program was initially designed to be implemented. in this study, the investigators test strategies to implement imgv in fqhcs, including training and coaching clinic staff, and measure the effectiveness of the imgv on health outcomes for patients with chronic pain.


Eligibility criteria:
inclusion criteria: * staff and clinicians at each clinic who are involved in implementation of the imgv. * only patients who have enrolled in the integrative medical group visit (imgv) programs for patients with chronic pain at their federally qualified health center will be eligible for enrollment in the study. physicians at each clinical site will determine enrollment criteria for their imgv program specific to their clinical site--patients who are enrolled in the program will then be invited to participate in the research study. exclusion criteria: * all staff, clinicians, and patients who are not involved in the imgv at the specific clinical sites are excluded from participation.
characteristics of intestinal microbiome following pancreatic surgery

Conditions: Pancreatic Cancer; Microbiota; Pancreatoduodenectomy

Summary: the goal of this observational study is to learn about intestinal microbiome structure and function in individuals who have undergone a pancreatoduodenectomy and compare to healthy matched controls. the primary objectives of the study are: 1. to explore and describe any differences in the gut microbiota especially shannon diversity index 2. to conduct functional profiling by exploring and describing any differences in functional metabolites produced in the gut in people having had pancreatoduodenectomy greater than 6 months ago compared to healthy matched controls. participants will be asked to complete the following: * three-day food, bowel and medication diary (see protocol appendix 5) * gastrointestinal symptom rating scale (see protocol appendix 6) * quality of life questionnaire (see protocol appendix 7) * stool sample test using microba insight trademark (a small swab is taken from soiled toilet paper, sealed in a room-temperature storage capsule and mailed to the testing laboratory)


Eligibility criteria:
inclusion criteria: * adults (aged equal to or greater than 18 years) having had pancreatoduodenectomy (whipple's) surgery between april 2018 - december 2023 for curative intent and received post-operative clinical management at royal prince alfred hospital, (post-surgical participants), and * healthy adults matched by age, sex, body mass index and smoking status exclusion criteria: * aged less than 18 years * are unable to complete the questionnaires or testing due to language or cognitive limitations * have active or recurring pancreatic cancer, or where the surgery was for non-curative intent * have other gastrointestinal conditions that could affect gut symptoms or microbiome such as inflammatory bowel disease, irritable bowel syndrome coeliac disease, or are currently pregnant or breastfeeding * are currently taking medications or diet that can affect gut symptoms or microbiome

Keywords: matched case control study
a phase 2b study of modified vaccinia virus to treat patients advanced liver cancer who failed sorafenib

Conditions: Hepatocellular Carcinoma; Liver Cancer; HCC

Summary: this study is to determine whether jx-594 (pexa-vec) plus best supportive care is more effective in improving survival than best supportive care in patients with advanced hepatocellular carcinoma (hcc) who have failed sorafenib.


Eligibility criteria:
key inclusion criteria: * diagnosis of primary hcc by tissue biopsy (histological/cytological diagnosis), or clinical diagnosis * previously treated with sorafenib for ≥ 14 days and has discontinued sorafenib treatment at least 14 days prior to randomization due to either intolerance or radiographic progression note: sorafenib is not required to be the most recent treatment received for hcc * ecog performance status 0, 1 or 2 * child-pugh class a; or child-pugh class b7 without clinically significant ascites * hematocrit ≥30% or hemoglobin ≥10 g/dl * tumor status: measurable viable tumor in the liver and injectable under imaging-guidance; at least one tumor in the liver that has not received prior local-regional treatment or that has exhibited \>25% growth in viable tumor size since prior local-regional treatment. key exclusion criteria: * received sorafenib within 14 days prior to randomization * received systemic anti-cancer therapy other than sorafenib within 28 days of randomization * prior treatment with jx-594 * platelet count \< 50,000 plt/ mm3 * total white blood cell count \< 2,000 cells/mm3 * prior or planned organ transplant * known significant immunodeficiency due to underlying illness (e.g. hiv/aids) and/or medication * severe or unstable cardiac disease * viable cns malignancy associated with clinical symptoms * pregnant or nursing an infant * history of inflammatory skin condition (e.g., eczema requiring previous treatment, atopic dermatitis)

Keywords: liver cancer liver tumor advanced hcc hepatocellular cancer jennerex hcc sorafenib sorafenib failure sorafenib intolerant nexavar nexavar failure jx594 oncolytic virus vaccinia viral therapy jx biotherapeutics hep018 traverse biologic pexa-vec